Current status and future perspective on the management of metastatic castration-sensitive prostate cancer

Hyuna Sung, 2021, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin., 0, 1 Montgomery, 2008, Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth, Cancer Res., 68, 4447, 10.1158/0008-5472.CAN-08-0249 Davison, 2006, Androgen physiology, Semin. Reprod. Med., 24, 71, 10.1055/s-2006-939565 Russell, 1994, STEROID 5α-REDUCTASE : TWO GENES /TWO ENZYMES, Annu. Rev. Biochem., 63, 25, 10.1146/annurev.bi.63.070194.000325 Prescott, 2006, Molecular chaperones throughout the life cycle of the androgen receptor, Cancer Lett., 231, 12, 10.1016/j.canlet.2004.12.037 Shiota, 2012, Pro-survival and anti-apoptotic properties of androgen receptor signaling by oxidative stress promote treatment resistance in prostate cancer, Endocr. Relat. Cancer, 19, 243, 10.1530/ERC-12-0232 Huggins, 1941, Studies on prostatic cancer i. the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate, Cancer Res., 1, 293 Mottet, 2021, EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer—2020 update. Part 1: screening, diagnosis, and local treatment with curative intent, Eur. Urol., 79, 243, 10.1016/j.eururo.2020.09.042 Shore, 2020, Oral relugolix for androgen-deprivation therapy in advanced prostate cancer, N. Engl. J. Med., 382, 2187, 10.1056/NEJMoa2004325 Mohler, 2019, Prostate cancer, version 2.2019, JNCCN J. Natl. Compr. Cancer Netw., 17, 479, 10.6004/jnccn.2019.0023 Dong, 2015, Intermittent hormone therapy versus continuous hormone therapy for locally advanced prostate cancer: a meta-analysis, Aging Male, 18, 233, 10.3109/13685538.2015.1065245 Hussain, 2013, Intermittent versus Continuous Androgen Deprivation in Prostate Cancer, N. Engl. J. Med., 368, 1314, 10.1056/NEJMoa1212299 Magnan, 2015, Intermittent vs continuous androgen deprivation therapy for prostate cancer, JAMA Oncol., 1, 1261, 10.1001/jamaoncol.2015.2895 Botrel, 2014, Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: a systematic review and meta-analysis, BMC Urol., 14, 1, 10.1186/1471-2490-14-9 Niraula, 2013, Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials, J. Clin. Oncol., 31, 2029, 10.1200/JCO.2012.46.5492 Hussain, 2016, Evaluating intermittent androgen-deprivation therapy phase III clinical trials: the devil is in the details, J. Clin. Oncol., 34, 280, 10.1200/JCO.2015.62.8065 Cornford, 2021, EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II—2020 update: treatment of relapsing and metastatic prostate cancer, Eur Urol., 79, 263, 10.1016/j.eururo.2020.09.046 Llukani, 2017, Aetiology and management of earlier vs later biochemical recurrence after retropubic radical prostatectomy, BJU Int., 120, 505, 10.1111/bju.13816 James, 2015, Survival with newly diagnosed metastatic prostate cancer in the docetaxel era: data from 917 patients in the control arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019), Eur Urol., 67, 1028, 10.1016/j.eururo.2014.09.032 Sweeney, 2015, Chemohormonal therapy in metastatic hormone-sensitive prostate cancer, N. Engl. J. Med., 373, 737, 10.1056/NEJMoa1503747 James, 2016, Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial, Lancet, 387, 1163, 10.1016/S0140-6736(15)01037-5 Gravis, 2013, Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial, Lancet Oncol., 14, 149, 10.1016/S1470-2045(12)70560-0 Kyriakopoulos, 2018, Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 chaarted trial, J. Clin. Oncol., 36, 1080, 10.1200/JCO.2017.75.3657 Clarke, 2019, Addition of docetaxel to hormonal therapy in low- And high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial, Ann. Oncol., 30, 1992, 10.1093/annonc/mdz396 Gravis, 2016, Androgen deprivation therapy (ADT) plus docetaxel versus ADT Alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial, Eur. Urol., 70, 256, 10.1016/j.eururo.2015.11.005 Vale, 2016, Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data, Lancet Oncol., 17, 243, 10.1016/S1470-2045(15)00489-1 Tucci, 2016, Addition of docetaxel to androgen deprivation therapy for patients with hormone-sensitive metastatic prostate cancer: a systematic review and meta-analysis, Eur. Urol., 69, 563, 10.1016/j.eururo.2015.09.013 Fizazi, 2015, Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra, Ann. Oncol., 26, 1660, 10.1093/annonc/mdv245 Sathianathen, 2018, Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer, Cochrane Database Syst. Rev., 10 Fizazi, 2019, Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial, Lancet Oncol., 20, 686, 10.1016/S1470-2045(19)30082-8 James, 2017, Abiraterone for prostate cancer not previously treated with hormone therapy, N. Engl. J. Med., 377, 338, 10.1056/NEJMoa1702900 Agarwal, 2022, Orteronel for metastatic hormone-sensitive prostate cancer: a multicenter, randomized, open-label phase III trial (SWOG-1216), J Clin Oncol, 10.1200/JCO.21.02517 Davis, 2019, Enzalutamide with standard first-line therapy in metastatic prostate cancer, N. Engl. J. Med., 381, 121, 10.1056/NEJMoa1903835 Armstrong, 2019, Arches: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer, J. Clin. Oncol., 37, 2974, 10.1200/JCO.19.00799 Armstrong, 2022, Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer, J. Clin. Oncol. Publ. Online, 1 Chi, 2019, Apalutamide for metastatic, castration-sensitive prostate cancer, N. Engl. J. Med., 381, 13, 10.1056/NEJMoa1903307 Wang, 2021, Comparison of systemic treatments for metastatic castration-sensitive prostate cancer: a systematic review and network meta-analysis, JAMA Oncol., 7, 412, 10.1001/jamaoncol.2020.6973 Rush, 2021, Quality of life in men with prostate cancer randomly allocated to receive docetaxel or abiraterone in the STAMPEDE trial, J. Clin. Oncol. Smith, 2022, Darolutamide and survival in metastatic, hormone-sensitive prostate cancer, N. Engl. J. Med., 386, 1132, 10.1056/NEJMoa2119115 Fizazi, 2022, Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design, Lancet, 10.1016/S0140-6736(22)00367-1 Hong, 2015, Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer, Nat. Commun., 6, 10.1038/ncomms7605 Gundem, 2015, The evolutionary history of lethal metastatic prostate cancer, Nature, 520, 353, 10.1038/nature14347 Ost, 2018, Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial, J. Clin. Oncol., 36, 446, 10.1200/JCO.2017.75.4853 Patrikidou, 2015, Locoregional symptoms in patients with de novo metastatic prostate cancer: morbidity, management, and disease outcome, Urol. Oncol. Semin. Orig. Investig., 33, 202 Boevé, 2019, Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical tria, Eur. Urol., 75, 410, 10.1016/j.eururo.2018.09.008 Boevé, 2021, Eur. Urol., 79, 188, 10.1016/j.eururo.2020.08.023 Parker, 2018, Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial, Lancet, 392, 2353, 10.1016/S0140-6736(18)32486-3 Burdett, 2019, Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: a STOPCAP systematic review and meta-analysis, Eur. Urol., 76, 115, 10.1016/j.eururo.2019.02.003 Satkunasivam, 2015, Radical prostatectomy or external beam radiation therapy vs no local therapy for survival benefit in metastatic prostate cancer: a SEER-medicare analysis, J. Urol., 194, 378, 10.1016/j.juro.2015.02.084 Culp, 2014, Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study, Eur. Urol., 65, 1058, 10.1016/j.eururo.2013.11.012 Fossati, 2015, Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a SEER-based Study, Eur. Urol., 67, 3, 10.1016/j.eururo.2014.08.056 Gratzke, 2014, Role of radical prostatectomy in metastatic prostate cancer: data from the munich cancer registry, Eur. Urol., 66, 602, 10.1016/j.eururo.2014.04.009 Gandaglia, 2017, Radical prostatectomy in men with oligometastatic prostate cancer: results of a single-institution series with long-term follow-up, Eur. Urol., 72, 289, 10.1016/j.eururo.2016.08.040 Antwi, 2014, Prognostic impact of definitive local therapy of the primary tumor in men with metastatic prostate cancer at diagnosis: a population-based, propensity score analysis, Cancer Epidemiol., 38, 435, 10.1016/j.canep.2014.04.002 Won, 2013, Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer, BJU Int., 112, 250, 10.1111/bju.12169 Sooriakumaran, 2021, Feasibility and safety of radical prostatectomy for oligo-metastatic prostate cancer: the testing radical prostatectomy in men with prostate cancer and oligo-metastases to the bone (TRoMbone) trial, BJU Int. Phillips, 2020, Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE Phase 2 randomized clinical trial, JAMA Oncol., 6, 650, 10.1001/jamaoncol.2020.0147 Blanchard, 2017, Rôle de la radiothérapie ablative des métastases chez les patients atteints de cancer de la prostate oligométastatique hormonosensible : un essai du Groupe d’étude des tumeurs urogénitales et de l'Association française d'urologie, Cancer Radiother., 21, 491, 10.1016/j.canrad.2017.06.007 Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur. J. Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 Han, 2018, Impact of 68Ga-PSMA PET on the Management of patients with prostate cancer: a systematic review and meta-analysis, Eur. Urol., 74, 179, 10.1016/j.eururo.2018.03.030 Perera, 2020, Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer—updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-, Eur. Urol., 77, 403, 10.1016/j.eururo.2019.01.049 Pasoglou, 2014, One-step TNM staging of high-risk prostate cancer using magnetic resonance imaging (MRI): toward an upfront simplified “all-in-one” imaging approach?, Prostate, 74, 469, 10.1002/pros.22764 Freitag, 2016, Comparison of hybrid 68Ga-PSMA PET/MRI and 68Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer, Eur. J. Nucl. Med. Mol. Imaging, 43, 70, 10.1007/s00259-015-3206-3 Sartor, 2021, Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer, N. Engl. J. Med., 385, 1091, 10.1056/NEJMoa2107322 Mollica V., et al., An insight on novel molecular pathways in metastatic prostate cancer : a focus on DDR , MSI and AKT, Int. J. Mol. Sci. 22 (24) (2021) 13519, doi: 10.3390/ijms222413519. Robinson, 2015, Integrative clinical genomics of advanced prostate cancer, Cell, 161, 1215, 10.1016/j.cell.2015.05.001 Armenia, 2018, The long tail of oncogenic drivers in prostate cancer, Nat. Genet., 50, 645, 10.1038/s41588-018-0078-z Shelley, 2010, Metastatic prostate cancer, 293 Jamaspishvili, 2018, Clinical implications of PTEN loss in prostate cancer, Nat. Rev. Urol., 15, 222, 10.1038/nrurol.2018.9 Huggins, 1972, Studies on prostatic cancer: I. The effect of castration, of estrogen and androgen phosphatases in metastatic carcinoma of the prostate, CA Cancer J. Clin., 22, 232, 10.3322/canjclin.22.4.232 Swami, 2020, Association of SPOP mutations with outcomes in men with de novo metastatic castration-sensitive prostate cancer, Eur. Urol., 78, 652, 10.1016/j.eururo.2020.06.033 Deek, 2021, The mutational landscape of metastatic castration-sensitive prostate cancer: the spectrum theory revisited, Eur. Urol., 80, 632, 10.1016/j.eururo.2020.12.040 Stopsack, 2020, Oncogenic genomic alterations, clinical phenotypes, and outcomes in metastatic castration-sensitive prostate cancer, Clin. Cancer Res., 26, 3230, 10.1158/1078-0432.CCR-20-0168 Kohli, 2020, Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer, EBioMedicine, 54, 10.1016/j.ebiom.2020.102728 Hussain, 2020, Survival with olaparib in metastatic castration-resistant prostate cancer, N. Engl. J. Med., 383, 2345, 10.1056/NEJMoa2022485 de Bono, 2020, Olaparib for metastatic castration-resistant prostate cancer, N. Engl. J. Med., 382, 2091, 10.1056/NEJMoa1911440 Abida, 2019, Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade, JAMA Oncol., 5, 471, 10.1001/jamaoncol.2018.5801 de Bono, 2021, Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial, Lancet Oncol., 22, 1250, 10.1016/S1470-2045(21)00376-4